摘要
目的评价顺铂、5-氟尿嘧啶热化疗治疗老年口腔颌面部恶性肿瘤的临床疗效及安全性。方法入选64例老年口腔颌面部恶性肿瘤患者,随机分为对照组31例与试验组33例,对照组用顺铂、5-氟尿嘧啶化疗方案,第1-3天,顺铂30 mg·m-2,静脉滴注;第1-5天,5-氟尿嘧啶500 mg·m-2,静脉滴注,21 d为一个周期。试验组在上述化疗方案的基础上联合局部超声热疗,温度在40-42℃,每次热化疗时间约40 min。2组共化疗5个周期,比较2组患者化疗临床疗效、外周血淋巴细胞水平（CD4＋、CD8＋及CD4＋/CD8＋）及不良反应发生率。结果对照组化疗客观有效率为29.03%,显著低于试验组的57.58%（P〈0.05）。对照组治疗前后外周血T淋巴细胞亚群水平差异无统计学意义（P〉0.05）;治疗后,试验组CD4＋、CD4＋/CD8＋水平比治疗前和对照组治疗后高（P〈0.05）。对照组化疗后不良反应总发生率为38.71%,试验组为39.39%,2组差异无统计学意义（P〉0.05）。结论顺铂、5-氟尿嘧啶联合超声热化疗可显著提高口腔颌面部恶性肿瘤的临床疗效,且不增加不良反应发生率。
Objective To evaluate the effects and safety of theramo-chemotherapy of DDP and 5-fluorouracil for elderly patients with oral and maxillofacial cancer. Methods Sixty-four patients with oral and maxillofacial cancer were recruited in the prospective study. The patients were randomized divided into control group（ n = 31） and treatment group（ n = 33）. Patients in the control group were given DDP 30 mg·m-2through intravenous drip on day 1 to 3 plus 5-FU 500 mg·m-2through intravenous drip on day 1 to 5. And patients in the treatment group received ultrasonic heat with temperature 40-42 ℃,40 minutes for each time in the period of chemotherapy on the basis of the treatment regime of control group. The treatment lasted for 5 cycles with 21 days a cycle.The data of clinical efficacy,T lymph cell sub-group changes and chemotherapy related adverse drug reactions were compared between the two groups. Results The objective response rate was 29. 03% and57. 58% in the control and treatment group respectively,with treatment group significantly higher than the control group（ P〈0. 05）. The T cell sub group in the control group were not statistically different before and after treatment（ P〈0. 05）. After treatment,the T cell sub group intreatment group was significantly higher than those of before treatment and control group. And the chemotherapy related adverse drug reactions between the two groups were not statistically different（ 38. 71% vs 39. 39%,P〈0. 05）.Conclusion DDP and 5-FU theramo-chemotherapy regimen can significantly improve the objective response rate of patients with oral and maxillofacial cancer,but not increasing the risk of developing chemotherapy related adverse drug reactions.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2015年第14期1399-1401,共3页
The Chinese Journal of Clinical Pharmacology
基金
丽水市科技局基金资助项目(20110414)
